Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer.

Next Previous
Trial Profile

Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Apr 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Letrozole (Primary) ; Fadrozole
  • Indications Advanced breast cancer
  • Focus Adverse reactions

Most Recent Events

  • 18 Apr 2012 Actual end date (Dec 2005) added as reported by ClinicalTrials.gov.
  • 17 Apr 2012 Actual patient number is 17 according to ClinicalTrials.gov.
  • 07 Sep 2007 Status changed from in progress to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top